Adel, A., Abushanab, D., Hamad, A., Abdulla, M., Izham, M., & Yassin, M. (2021). Assessment of Dasatinib Versus Nilotinib as Upfront Therapy for Chronic Phase of Chronic Myeloid Leukemia in Qatar: A Cost-Effectiveness Analysis. Cancer Control.

Adel, Ahmad, Dina Abushanab, Anas Hamad, Mohammad Abdulla, Mohamed Izham, ja Mohamed Yassin. "Assessment of Dasatinib Versus Nilotinib As Upfront Therapy for Chronic Phase of Chronic Myeloid Leukemia in Qatar: A Cost-Effectiveness Analysis." Cancer Control 2021.

Adel, Ahmad, et al. "Assessment of Dasatinib Versus Nilotinib As Upfront Therapy for Chronic Phase of Chronic Myeloid Leukemia in Qatar: A Cost-Effectiveness Analysis." Cancer Control 2021.